Stifel Nicolaus assumed coverage on shares of Atreca (NASDAQ:BCEL) in a research report report published on Monday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $28.00 price objective on the stock.
Other analysts also recently issued research reports about the company. Cowen reiterated a buy rating on shares of Avrobio in a research report on Monday. Evercore ISI assumed coverage on Akero Therapeutics in a research report on Monday. They issued an outperform rating and a $35.00 target price for the company. Finally, Canaccord Genuity assumed coverage on Slack in a research report on Monday. They issued a buy rating and a $40.00 target price for the company.
BCEL stock opened at $16.00 on Monday. Atreca has a twelve month low of $14.26 and a twelve month high of $20.00.
Atreca Company Profile
Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Recommended Story: Capital gains and your 401(k) or IRA
Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.